BATON ROUGE, La. — The specialty chemical maker Albermarle Corp. (NYSE: ALB) said Tuesday that its plant in South Haven has expanded and upgraded its capabilities for making active pharmaceutical ingredients.
The plant is registered with the United States Food and Drug Administration and follows Current Good Manufacturing Processes. Production using the new expanded capacity started June 1. The plant follows Current Good Manufacturing Practices, a series of general principles that must be observed during manufacturing, with the clear goal of protecting public health.
This expansion is the latest in a series of projects at the South Haven site to increase capabilities and production throughput, meeting the increasing demand for both generic API products and custom manufacturing service portfolios.
In the past two years, the number of custom API projects has more than doubled at the South Haven site. The investment matches the solids handling equipment with the reactor capacity and will enable the company to advance its growing portfolio of custom API products, several of which have progressed to late stage clinical development and pre-registration status.
Albemarle, based in Baton Rouge, La., is a leading global developer, manufacturer, and marketer of highly-engineered specialty chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, automotive/transportation, pharmaceuticals, crop protection, food-safety and custom chemistry services. Albemarle employs approximately 4,000 people and serves customers in approximately 100 countries.
More at www.albemarle.com.